Generated Narrative: Evidence 6512 version: 3; Last updated: 2026-08-06 09:26:00+0000 ArtifactPublicationStatus: Active url: https://fevir.net/resources/Evidence/6512 identifier: FEvIR Object Identifier/6512 name: OSFPreprint_PrimaryOutcomeMeasure_0_OutcomeAnalysis_0_BetweenGroupAnalysis_OG000_OG001 title: Percentage of Participants With Clinical Recovery Within 14 Days After Randomization Statistical Analysis for Nigella Sativa Oil vs Control in Nigella Sativa for COVID-19 OSF Preprint citeAs: Percentage of Participants With Clinical Recovery Within 14 Days After Randomization Statistical Analysis for Nigella Sativa Oil vs Control in Nigella Sativa for COVID-19 OSF Preprint [Database Entry: FHIR Evidence Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 6512. Revised 2021-07-19. Available at: https://fevir.net/resources/Evidence/6512. Computable resource at: https://fevir.net/resources/Evidence/6512#json. status: Active date: 2021-07-19 21:20:42+0000 author: Brian S. Alper: publisher: Computable Publishing LLC contact: support@computablepublishing.com copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/ description: This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide. variableDefinition description: Adult symptomatic patients with mild COVID-19 were recruited between May and August 2020 from King Abdulaziz University Hospital in Jeddah, Saudi Arabia. variableRole: Population observed: Group NCT04401202_Enrollment_Group intended: NCT04401202 Eligibility Criteria variableDefinition description: Nigella Sativa Oil (NSO) variableRole: Exposure observed: supplementation with oral capsules of NSO (MARNYS® Cuminmar 500 mg twice daily for 10 days) plus standard of care variableDefinition description: Control variableRole: Exposure observed: standard of care medications alone variableDefinition description: proportion of patients recovered (free of symptoms for 3 days) within 14 days after randomization variableRole: Outcome observed: Percentage of Participants With Clinical Recovery Within 14 Days After Randomization statistic description: There were 47 patients in the treatment group (NSO) and 47 patients in the control group. The proportion of patients recovered in the treatment group was significantly higher than the control group, 37 (79%) versus 21 (45%) (p=0.001). numberAffected: 58 SampleSizes - NumberOfStudies KnownDataCount * 1 94 AttributeEstimates - Type Quantity * P-value 0.001
Percentage of Participants With Clinical Recovery Within 14 Days After Randomization Statistical Analysis for Nigella Sativa Oil vs Control in Nigella Sativa for COVID-19 OSF Preprint
Percentage of Participants With Clinical Recovery Within 14 Days After Randomization Statistical Analysis for Nigella Sativa Oil vs Control in Nigella Sativa for COVID-19 OSF Preprint [Database Entry: FHIR Evidence Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 6512. Revised 2021-07-19. Available at: https://fevir.net/resources/Evidence/6512. Computable resource at: https://fevir.net/resources/Evidence/6512#json.
This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.
Adult symptomatic patients with mild COVID-19 were recruited between May and August 2020 from King Abdulaziz University Hospital in Jeddah, Saudi Arabia.
supplementation with oral capsules of NSO (MARNYS® Cuminmar 500 mg twice daily for 10 days) plus standard of care
proportion of patients recovered (free of symptoms for 3 days) within 14 days after randomization
Percentage of Participants With Clinical Recovery Within 14 Days After Randomization
There were 47 patients in the treatment group (NSO) and 47 patients in the control group. The proportion of patients recovered in the treatment group was significantly higher than the control group, 37 (79%) versus 21 (45%) (p=0.001).